Rivaroxaban: A review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery

Drugs

Volumn 69, Issue 13, 2009, Pages 1829-1851

  Duggan, Sean T ^a   Scott, Lesley J ^b   Plosker, Greg L ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; CARBAMAZEPINE; CLOPIDOGREL; CYTOCHROME; CYTOCHROME P450; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; DABIGATRAN; DIGOXIN; ENOXAPARIN; FONDAPARINUX; HYPERICUM EXTRACT; KETOCONAZOLE; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PLACEBO; PROTHROMBIN; RANITIDINE; RIFAMPICIN; RIVAROXABAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XARELTO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD CLOT LYSIS; CANADA; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPRESSION GARMENT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FECES; FEVER; HEALTH CARE; HUMAN; IN VITRO STUDY; INCIDENCE; INDUCED HYPOTENSION; INSOMNIA; LIVER ENZYME BLOOD LEVEL; LIVRE ENZYME BLOOD LEVEL; LUNG EMBOLISM; MONOTHERAPY; MORTALITY; NAUSEA; NONHUMAN; ORTHOPEDIC SURGERY; PERIPHERAL EDEMA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; QT INTERVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SPAIN; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES; URINE; VENOUS THROMBOEMBOLISM; VOMITING; WOUND FLUID;

ANIMALS; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CLINICAL TRIALS AS TOPIC; HUMANS; MORPHOLINES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 69749106585     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11200890-000000000-00000     Document Type: Review

References (74)

1. Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003; 163 (7): 759-68
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008 Jun; 133 (6 Suppl.): 381-453S
3. Dalen JE, Paraskos JA, Ockene IS, et al. Venous throm- boembolism: scope of the problem. Chest 1986 May; 89 (5 Suppl.): 370-433S
4. Department of Health. Report of the independent expert working group on the prevention of venous thromboem-bolism in hospitalised patients [online]. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH-073944 [Accessed 2009 Mar 2]
5. Dahl OE. Orthopaedic surgery as a model for drug devel- opment in thrombosis. Drugs 2004; 64 Suppl. 1: 17-25
6. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125 (1): 1-7
7. Eriksson BI, Quinlan DJ, Weitz JI, et al. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48 (1): 1-22
8. Eriksson BI, Quinlan DJ. Oral anticoagulants in develop- ment: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006; 66 (11): 1411-29
9. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor Xa inhibitor. J Thromb Haemost 2005 Mar; 3 (3): 514-21
10. Depasse F, Busson J, Mnich J, et al. Effect of BAY 59-7939: a novel, oral direct factor Xa inhibitor on clot-bound factor Xa activity in vitro [abstract no. P1104]. J Thromb Hae-most 2005 Aug 6-2005; 3 Suppl. 1: P1104
11. Laux V, Perzborn E, Kubitza D, et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007 Jul; 33 (5): 515-23
12. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl} methyl) thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005 Sep 22; 48 (19): 5900-8
13. Bayer Schering Pharma. Xarelto® (rivaroxaban 10mg ta- blets): EU summary of product characteristics [online]. Available from URL: http://www.xarelto.com/html/downloads/Xarelto-Summary-of-Product- Characteristics-30Sept2008.pdf [Accessed 2008 Nov 22]
14. Perzborn E, Lange U. Rivaroxaban: an oral, direct factor Xa inhibitor inhibits tissue factor-mediated platelet aggregation [abstract no. P-W-642]. J Thromb Haemost 2007 Aug; 5 Suppl. 2: P-W-642
15. Wong PC, Crain E, Watson C, et al. Comparative anti- thrombotic and antihemostatic effects of the direct factor Xa inhibitors, apixaban and rivaroxaban, and the direct thrombin inhibitors, dabigatran and lepirudin, in rabbit models of venous thrombosis and bleeding time [abstract no. 3025]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Francisco (CA)
16. Kubitza D, Becka M, Voith B, et al. Safety, pharmacody- namics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005 Oct; 78 (4): 412-21
17. Kubitza D, Becka M, Wensing G, et al. Safety, pharmaco- dynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005 Dec; 61 (12): 873-80
18. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther 2007 Jun; 45 (6): 335-44
19. Mueck W, Borris LC, Dahl OE, et al. Population pharma- cokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008 Sep; 100 (3): 453-61
20. Mueck W, Eriksson BI, Bauer KA, et al. Population phar- macokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47 (3): 203-16
21. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007 Nov; 47 (11): 1398-407
22. Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban [letter]. J Thromb Haemost 2007 Apr; 5 (4): 886-8
23. Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban - an oral, direct factor Xa inhibitor - has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol 2008 Jul 30; 143: 92-9
24. Kubitza D, Becka M, Mueck W, et al. Rivaroxaban (BAY 59-7939) - an oral, direct factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007 Apr; 63 (4): 469-76
25. Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factor Xa inhibitor - are not affected by aspirin. J Clin Pharmacol 2006 Sep; 46 (9): 981-90
26. Kubitza D, Becka M, Mueck W, et al. Co-administration of rivaroxaban - a novel, oral, direct factor Xa inhibitor - and clopidogrel in healthy subjects [abstract no. 1272]. Eur Heart J 2007 Sep; 28 (Abstr. Suppl.): 189
27. Kubitza D, Mueck W, Becka M. Randomized, double- blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf 2008; 31 (1): 67-77
28. Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007 Feb; 47 (2): 218-26
29. Kubitza D, Becka M, Zuehlsdorf M, et al. Effects of single- dose BAY 59-7939 - an oral, direct factor Xa inhibitor - in subjects with extreme body weight [abstract no. 1872]. Blood 2005 Nov 16; 106 (11): 532
30. Halabi A, Maatouk H, Klause N, et al. Effects of renal im- pairment on the pharmacology of rivaroxaban - an oral, direct, factor Xa inhibitor [abstract no. 913]. Blood 2006 Nov 1; 108 (11): 274
31. Kubitza D, Becka M, Mueck W, et al. The effect of age and gender on the pharmacology and safety of the oral, direct factor Xa inhibitor rivaroxaban [abstract no. P-T-628]. 21st Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6-12; Geneva
32. Kubitza D, Becka M, Mueck W, et al. The effect of extreme age, and gender on the pharmacology and tolerability of rivaroxaban: an oral, direct factor Xa inhibitor. Blood 2006; 108 (11): 271-2
33. Kubitza D, Becka M, Voith B, et al. Effect of enoxaparin on the safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY 59-7939: an oral, direct factor Xa inhibitor [abstract no. P1704]. J Thromb Haemost 2005; 3 Suppl. 1: P1704
34. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006 May; 46 (5): 549-58
35. Bayer Inc. Xarelto® (rivaroxaban 10mg tablets): product monograph [online]. Available from URL: http://bayer.ca/files/XARELTO-PM-ENG-10SEP2008- 119111pdf?# [Accessed 2009 Feb 25]
36. Lang D, Freudenberger C, Weinz C. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos 2009 Feb 5; 37 (5): 1046-55
37. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009 Feb 5; 37 (5): 1056-64
38. Kubitza D, Becka M, Zuehlsdorf M, et al. No interaction between the novel, oral, direct factor Xa inhibitor BAY 59-7939 and digoxin [abstract no. 11]. J Clin Pharmacol 2006; 46: 702
39. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006 Jan; 4 (1): 121-8
40. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006 Nov 28; 114 (22): 2374-81
41. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost 2005 Nov; 3 (11): 2479-86
42. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008 Jun 26; 358 (26): 2765-75
43. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 Jun 26; 358 (26): 2776-86
44. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. Lancet 2009 May 16; 373 (9676): 1673-80
45. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip ar-throplasty: a double-blind, randomised controlled trial. Lancet 2008 Jul 5; 372 (9632): 31-9
46. Turpie AG, Lassen MR, Kakkar AK. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effect on symptomatic venous thromboembolism, death, and bleeding [abstract no. 36]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Fransisco (CA)
47. Bauer KA, Homering M, Berkowitz SD, et al. Effects of age, weight, gender and renal function in a pooled analysis of four phase III studies of rivaroxaban for prevention of venous thromboembolism after major orthopaedic surgery [abstract no. 436]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Francisco (CA)
48. Johnson and Johnson Pharmaceutical Research and Devel- opment L.L.C. Rivaroxaban for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery. FDA advisory committee briefing book [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4418b1-03-Johnson-Johnson. pdf [Accessed 2009 Jul 17]
49. Eriksson BI, Turpie AG, Lassen MR, et al. A pooled ana- lysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effects of specified co-medications [abstract no. 1986]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Fransisco (CA)
50. Diamantopoulos A, Forster F, Lees M, et al. Cost-effec- tiveness of rivaroxaban versus enoxaparin for thrombo-prophylaxis after total hip replacement in the UK [abstract no. PHC9]. Value Health 2008 Nov; 11 (6): A534. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual European Congress; 2008 Nov 8-11; Athens
51. Diamantopoulos A, Forster F, Brosa M, et al. Cost-effec- tiveness of rivaroxaban versus enoxaparin for thrombo-prophylaxis after total hip replacement in Spain [abstract no. PHC6]. Value Health 2008 Nov; 11 (6): A533. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual European Congress; 2008 Nov 8-11; Athens
52. Kwong L, Diamantopoulos A, Forster F, et al. Will rivar- oxaban be cost-effective for prevention of venous throm-boembolism after total hip replacement in US patients? [abstract no. 1290 plus poster]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Francisco (CA)
53. Wells P, Diamantopoulos A, Forster F, et al. Cost-effec- tiveness of rivaroxaban as VTE prophylaxis after total hip replacement in Canada [abstract no. 1291 plus poster]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Francisco (CA)
54. Diamantopoulos A, Forster F, Brosa M, et al. Cost-effec- tiveness of rivaroxaban versus enoxaparin for thrombo-prophylaxis after total knee replacement in the UK and Spain [abstract no. PHC8]. Value Health 2008 Nov; 11 (6): A533-4 Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual European Congress; 2008 Nov 8-11; Athens
55. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 170. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA170Guidance.pdf [Accessed 2009 Apr 24]
56. National Institute for Health and Clinical Excellence. Costing statement: rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults [online]. Available from URL: http://www.nice.org.uk/guidance/index.jsp?action=download=43807 [Accessed 2009 Apr 30]
57. Johnson and Johnson Pharmaceutical Research and Devel- opment L.L.C. Johnson and Johnson Pharmaceutical Research and Development, L.L.C. submits new drug application to FDA for rivaroxaban [media release]. 2008 Jul 30 [online]. Available from URL: http://www.jnjphar marnd.com [Accessed 2009 Feb 2]
58. Eikelboom JW, Karthikeyan G, Fagel N, et al. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembo-lism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009 Feb; 135 (2): 513-20
59. American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. Adopted by the American Academy of Orthopedic Surgeons board of directors May 2007 [online]. Available from URL: www.aaos.org/research/ guidelines/ PE-guideline.pdf. [Accessed 2009 May 22]
60. National Institute for Health and Clinical Excellence. Ve- nous thromboembolism. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE clinical guideline 46 [online]. Available from URL: http://www.nice.org.uk/ guidance/index.jsp?action=download=30469 [Accessed 2009 Feb 2]
61. Nicolaides AN, Fareed J, Kakkar AK. Prevention and treatment of venous thromboembolism: international consensus statement (guidelines according to scientific evidence). Int Angiol 2006 Jun; 25 (2): 101-61
62. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007 Jun; 89 (6): 799-807
63. Amin AN, Stemkowski S, Lin J, et al. Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis? [letter]. Thromb Haemost 2008 Apr; 99 (4): 796-7
64. Reynolds NA, Perry CM, Scott LJ. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs 2004; 64 (14): 1575-96
65. Mori S, Matsuura A, Rama Prasad YV, et al. Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats. Biol Pharm Bull 2004 Mar; 27 (3): 418-21
66. European Medicines Agency. European public assessment report. Pradexa [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ pradaxa/H-829-PI-en.pdf [Accessed 2009 Feb 25]
67. Boehringer Ingelheim Canada Ltd. Pradax™ (dabigatran etexilate capsules 75mg and 110mg): product monograph [online]. Available from URL: http://www.boehringer-ingelheim.ca/ethical/products/pm/Pradax-Capsules.pdf [Accessed 2009 Apr 24]
68. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008 Mar; 28 (3): 380-6
69. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med Wkly 2007 Feb 7; 139 (5-6): 60-4
70. Carter NJ, McCormack PL, Plosker GL. Enoxaparin: a review of its use in ST-segment elevation myocardial infarction. Drugs 2008; 68 (5): 691-710
71. Lu G, DeGuzman FR, Lakhotia S, et al. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors [abstract no. 983]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Francisco (CA)
72. Gruber A, Marzec UM, Buetehorn U, et al. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivarox-aban in primates [abstract no. 3825]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Francisco (CA)
73. Fareed J, Ma Q, Florian M, et al. Differentiation of low- molecular-weight heparins: impact on the future of the management of thrombosis. Semin Thromb Hemost 2004 Feb; 30 Suppl. 1: 89-104
74. Diamantopoulos A, LeReun C, Rasul F, et al. Indirect comparisons of rivaroxaban vs alternative prophylaxis for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement [abstract no. 1292]. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Fransisco (CA)